Wan-Lu Yue
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Wan-Lu Yue has a total of 15 co-authors. Here are the top co-authors by number of shared publications:
- Gang Qin
Joint Division of Clinical Epidemiology, Affiliated Hospital of Nantong University, School of Public Health of Nantong University, Nantong, China
2 shared publications - Jun-Jie Mao
Cancer Research Center, Affiliated Tumor Hospital of Nantong University, Nantong, Jiangsu, China
2 shared publications - Xiao Zang
Division of Health Policy and Management, School of Public Health University of Minnesota Minneapolis MN USA
2 shared publications Bin Zhang
Department of Infectious Diseases, Affiliated Hospital of Nantong University, Medical School of Nantong University, Nantong, Jiangsu, China
1 shared publication- Chun-Hu Li
Joint Division of Clinical Epidemiology, Affilated Hosptial of Nantong University, School of Public Health of Nantong University, Nantong, Jiangsu, China
1 shared publication - Jian Feng
Department of Respiratory and Critical Care Medicine, The Affiliated Hospital of Nantong University, Nantong, China
1 shared publication
Latest Publications
- Open Access
- 20 September 2024
- Published by BMJ in BMJ Public Health
- Vol. 2 (2) , e001042
Health and economic impacts of Vaccae vaccination incorporating active case finding in India and South Africa: a modelling study
Introduction: Tuberculosis (TB) is a major global health issue, particularly, in India and South Africa. We aim to evaluate the potential of the new TB vaccine, Vaccae, to enhance TB control by integrating with active case finding (ACF) strategies in these regions. Methods: Using age-structured dynamic models, we projected the epidemiological and economic outcomes of combining Vaccae vaccination with ACF over 27 years. In India, four age-targeted strategies were analysed: (1) adolescent (15 years), (2) adolescent and young adult (AYA, 15–34 years), (3) adult (18–55 years) and (4) elderly (60+ years). In South Africa, strategies were based on HIV status: (1) HIV-targeted, (2) non-HIV and (3) general population. The vaccine efficacy of Vaccae was set at 54.7%, priced at US$120 per course. Outcomes measured included reductions in TB incidence and mortality, prioritised based on budget, incremental cost-effectiveness ratios (ICER) and benefit-cost ratios (BCR). Results: In India, the adult strategy could prevent 8.70 (95% UI: 6.86–11.13) million TB cases and 0.61 (0.39–0.91) million deaths, reducing incidence and mortality by 20.1% (18.7%–23.5%) and 19.0% (17.5%–22.5%), respectively. In South Africa, the general population strategy could avert 0.67 (0.45–0.99) million TB cases and 0.21 (0.15–0.28) million deaths, reducing incidence by 28.1% (26.1%–30.3%) and mortality by 27.0% (23.5%–30.0%). The vaccination budgets for the AYA strategy in India and the HIV-targeted strategy in South Africa were US$14.0 (10.14–23.29) billion and US$0.09 (0.06–0.15) billion, respectively. The ICERs were US$1082 (927–1426) and US$70 (53–123) per disability-adjusted life year averted, and the BCRs were 2.0 (1.6–2.4) and 176 (83.4–255.3), respectively. Thus, the AYA strategy in India and the HIV-targeted strategy in South Africa were the most favourable. Conclusion: Integrating Vaccae vaccination with ACF could significantly enhance TB control in high-burden countries. Policymakers should consider these strategies, with further research needed to confirm the findings.
- 20 September 2024
- Published by BMJ in BMJ Public Health
- Vol. 2 (2) , e001042
Open AccessHealth and economic impacts of Vaccae vaccination incorporating active case finding in India and South Africa: a modelling study
Introduction: Tuberculosis (TB) is a major global health issue, particularly, in India and South Africa. We aim to evaluate the potential of the new TB vaccine, Vaccae, to enhance TB control by integrating with active case finding (ACF) strategies in these regions. Methods: Using age-structured dynamic models, we projected the epidemiological and economic outcomes of combining Vaccae vaccination with ACF over 27 years. In India, four age-targeted strategies were analysed: (1) adolescent (15 years), (2) adolescent and young adult (AYA, 15–34 years), (3) adult (18–55 years) and (4) elderly (60+ years). In South Africa, strategies were based on HIV status: (1) HIV-targeted, (2) non-HIV and (3) general population. The vaccine efficacy of Vaccae was set at 54.7%, priced at US$120 per course. Outcomes measured included reductions in TB incidence and mortality, prioritised based on budget, incremental cost-effectiveness ratios (ICER) and benefit-cost ratios (BCR). Results: In India, the adult strategy could prevent 8.70 (95% UI: 6.86–11.13) million TB cases and 0.61 (0.39–0.91) million deaths, reducing incidence and mortality by 20.1% (18.7%–23.5%) and 19.0% (17.5%–22.5%), respectively. In South Africa, the general population strategy could avert 0.67 (0.45–0.99) million TB cases and 0.21 (0.15–0.28) million deaths, reducing incidence by 28.1% (26.1%–30.3%) and mortality by 27.0% (23.5%–30.0%). The vaccination budgets for the AYA strategy in India and the HIV-targeted strategy in South Africa were US$14.0 (10.14–23.29) billion and US$0.09 (0.06–0.15) billion, respectively. The ICERs were US$1082 (927–1426) and US$70 (53–123) per disability-adjusted life year averted, and the BCRs were 2.0 (1.6–2.4) and 176 (83.4–255.3), respectively. Thus, the AYA strategy in India and the HIV-targeted strategy in South Africa were the most favourable. Conclusion: Integrating Vaccae vaccination with ACF could significantly enhance TB control in high-burden countries. Policymakers should consider these strategies, with further research needed to confirm the findings.
- Open Access
- 31 May 2023
- Published by BMJ in BMJ Global Health
- Vol. 8 (5) , e012306
Population-level health and economic impacts of introducing Vaccae vaccination in China: a modelling study
Introduction Given the ageing epidemic of tuberculosis (TB), China is facing an unprecedented opportunity provided by the first clinically approved next-generation TB vaccine Vaccae, which demonstrated 54.7% efficacy for preventing reactivation from latent infection in a phase III trial. We aim to assess the population-level health and economic impacts of introducing Vaccae vaccination to inform policy-makers. Methods We evaluated a potential national Vaccae vaccination programme in China initiated in 2024, assuming 20 years of protection, 90% coverage and US$30/dose government contract price. An age-structured compartmental model was adapted to simulate three strategies: (1) no Vaccae; (2) mass vaccination among people aged 15–74 years and (3) targeted vaccination among older adults (60 years). Cost analyses were conducted from the healthcare sector perspective, discounted at 3%. Results Considering postinfection efficacy, targeted vaccination modestly reduced TB burden (~20%), preventing cumulative 8.01 (95% CI 5.82 to 11.8) million TB cases and 0.20 (0.17 to 0.26) million deaths over 2024–2050, at incremental cost-effectiveness ratio of US$4387 (2218 to 10 085) per disability adjusted life year averted. The implementation would require a total budget of US$22.5 (17.6 to 43.4) billion. In contrast, mass vaccination had a larger bigger impact on the TB epidemic, but the overall costs remained high. Although both preinfection and postinfection vaccine efficacy type might have a maximum impact (>40% incidence rate reduction in 2050), it is important that the vaccine price does not exceed US$5/dose. Conclusion Vaccae represents a robust and cost-effective choice for TB epidemic control in China. This study may facilitate the practice of evidence-based strategy plans for TB vaccination and reimbursement decision making.
- 31 May 2023
- Published by BMJ in BMJ Global Health
- Vol. 8 (5) , e012306
Open AccessPopulation-level health and economic impacts of introducing Vaccae vaccination in China: a modelling study
Introduction Given the ageing epidemic of tuberculosis (TB), China is facing an unprecedented opportunity provided by the first clinically approved next-generation TB vaccine Vaccae, which demonstrated 54.7% efficacy for preventing reactivation from latent infection in a phase III trial. We aim to assess the population-level health and economic impacts of introducing Vaccae vaccination to inform policy-makers. Methods We evaluated a potential national Vaccae vaccination programme in China initiated in 2024, assuming 20 years of protection, 90% coverage and US$30/dose government contract price. An age-structured compartmental model was adapted to simulate three strategies: (1) no Vaccae; (2) mass vaccination among people aged 15–74 years and (3) targeted vaccination among older adults (60 years). Cost analyses were conducted from the healthcare sector perspective, discounted at 3%. Results Considering postinfection efficacy, targeted vaccination modestly reduced TB burden (~20%), preventing cumulative 8.01 (95% CI 5.82 to 11.8) million TB cases and 0.20 (0.17 to 0.26) million deaths over 2024–2050, at incremental cost-effectiveness ratio of US$4387 (2218 to 10 085) per disability adjusted life year averted. The implementation would require a total budget of US$22.5 (17.6 to 43.4) billion. In contrast, mass vaccination had a larger bigger impact on the TB epidemic, but the overall costs remained high. Although both preinfection and postinfection vaccine efficacy type might have a maximum impact (>40% incidence rate reduction in 2050), it is important that the vaccine price does not exceed US$5/dose. Conclusion Vaccae represents a robust and cost-effective choice for TB epidemic control in China. This study may facilitate the practice of evidence-based strategy plans for TB vaccination and reimbursement decision making.